Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 6/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6814271 | 0.87 | MAPT (0.47) | MAPTALDH1A1LMNAS1PR4MAPK1 | |
| SCHEMBL6641770 | 0.86 | ALDH1A1 (0.51) | MAPTALDH1A1LMNAS1PR4MAPK1 | |
| SCHEMBL13832434 | 0.85 | GAA (0.52) | MAPTALDH1A1LMNAS1PR4MAPK1 | |
| SCHEMBL11661312 | 0.84 | ALDH1A1 (0.48) | MAPTALDH1A1LMNAS1PR4HPGD | |
| SCHEMBL6810975 | 0.82 | MAPT (0.45) | MAPTALDH1A1LMNAS1PR4MAPK1 | |
| SCHEMBL2794810 | 0.81 | MAPT (0.49) | MAPTALDH1A1LMNAS1PR4MAPK1 | |
| SCHEMBL6814794 | 0.81 | MAPT (0.52) | MAPTALDH1A1LMNAS1PR4MAPK1 | |
| SCHEMBL6815549 | 0.81 | MAPT (0.49) | MAPTALDH1A1LMNAS1PR4MAPK1 | |
| SCHEMBL13229879 | 0.80 | MAPT (0.51) | MAPTALDH1A1LMNAS1PR4MAPK1 | |
| SCHEMBL6814094 | 0.80 | MAPT (0.43) | MAPTALDH1A1LMNAS1PR4MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170247341-A1 | PHARMACEUTICALLY ACTIVE PYRAZINE DERIVATIVES | SENTINEL ONCOLOGY LIMITED (GB) | 2017-08-31 | — | — | US | disclosed |
| US-9630931-B2 | Pharmaceutically active pyrazine derivatives | SENTINEL ONCOLOGY LIMITED (GB) | 2017-04-25 | — | — | US | disclosed |
| US-9630931-B2 | Pharmaceutically active pyrazine derivatives | SENTINEL ONCOLOGY LIMITED (GB) | 2017-04-25 | — | — | US | disclosed |
| US-9630931-B2 | Pharmaceutically active pyrazine derivatives | SENTINEL ONCOLOGY LIMITED (GB) | 2017-04-25 | — | — | US | disclosed |
| EP-2780331-B1 | PHARMACEUTICALLY ACTIVE PYRAZINE DERIVATIVES | SENTINEL ONCOLOGY LTD (GB) | 2016-04-20 | — | — | EP | disclosed |
| EP-2780331-B1 | PHARMACEUTICALLY ACTIVE PYRAZINE DERIVATIVES | SENTINEL ONCOLOGY LTD (GB) | 2016-04-20 | — | — | EP | disclosed |
| US-20140323484-A1 | Pharmaceutically Active Pyrazine Derivatives | SENTINEL ONCOLOGY LIMITED (GB) | 2014-10-30 | — | — | US | disclosed |
| US-20140323484-A1 | Pharmaceutically Active Pyrazine Derivatives | SENTINEL ONCOLOGY LIMITED (GB) | 2014-10-30 | — | — | US | disclosed |
| US-20140323484-A1 | Pharmaceutically Active Pyrazine Derivatives | SENTINEL ONCOLOGY LIMITED (GB) | 2014-10-30 | — | — | US | disclosed |
| EP-2780331-A1 | PHARMACEUTICALLY ACTIVE PYRAZINE DERIVATIVES | Sentinel Oncology Limited (GB) | 2014-09-24 | — | — | EP | disclosed |
| WO-2013072502-A1 | PHARMACEUTICALLY ACTIVE PYRAZINE DERIVATIVES | SENTINEL ONCOLOGY LIMITED (GB) | 2013-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323484-A1 | Pharmaceutically Active Pyrazine Derivatives | PHKG1, PHKG2, PLK2 | MAPT 4356/4885ALDH1A1 3558/4885LMNA 4148/4885 |
| US-20170247341-A1 | PHARMACEUTICALLY ACTIVE PYRAZINE DERIVATIVES | PHKG1, PHKG2, PEAK1 | MAPT 4489/4885ALDH1A1 3827/4885LMNA 4238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.